30-Second Takeaway
- Bioengineered autologous dermo-epidermal grafts enable high expansion ratios with minimal scarring versus split-thickness grafts.
- Prospective data support lymphovenous bypass as a safe, effective physiologic option for secondary lymphedema.
- Adipose-derived cells and small-molecule microneedles show promise for acne scar remodeling and scar prevention.
- Next-generation hydrogels and aerogels support minimally invasive repair and advanced wound management.
- Bio-adaptive hydrogels can guide organized cartilage formation for segmental airway reconstruction.
Week ending December 20, 2025
Regenerative, microsurgical, and biomaterial advances reshaping burn, lymphedema, scar, and complex soft-tissue care
denovoSkin enables high expansion ratios and minimal scarring versus STSG in deep burns
This multicenter intra-patient randomized phase IIb trial compared denovoSkin™ with split-thickness skin grafts in adolescents and adults with deep burns. Two similar defects per patient were randomized to denovoSkin or STSG, with follow-up to 12 months. The mean expansion ratio was much higher with denovoSkin than STSG (10.76 vs 1.70; p < 0.001), indicating major donor-site sparing. By 3 months both areas were epithelialized, but denovoSkin sites had minimal scarring versus predominantly hypertrophic scarring for STSG. Safety was comparable, with only two denovoSkin-related serious adverse events that resolved spontaneously.
Prospective meta-analysis supports lymphovenous bypass for secondary lymphedema
This meta-analysis pooled eight prospective studies including 431 patients undergoing lymphovenous bypass with about 22 months mean follow-up. An average of 3.4 lymphovenous anastomoses were created per patient, reflecting contemporary supermicrosurgical practice. Lymphovenous bypass achieved a mean 14.26% limb-volume reduction at one year (95% CI 6.63–21.88; p < 0.0001). Approximately 46% of patients reduced or discontinued compression therapy (95% CI 24.9–69.1%; p < 0.01), with fewer cellulitis episodes reported. Across studies, LVB was considered safe, supporting its role as a durable physiologic adjunct to conservative management.
Immunometabolism drives chronic foreign body response and fibrosis around implants
This review links immune-cell energy metabolism to long-lasting inflammation and fibrotic foreign body responses around implants. High glucose uptake by immune cells is highlighted as a key driver of persistent inflammation and scar capsule formation. The authors propose targeting metabolic pathways in macrophages and other immune cells to attenuate fibrotic encapsulation. These concepts suggest metabolic modulation could complement device design to reduce capsule formation and implant-associated fibrosis.
References
Numbered in order of appearance. Click any reference to view details.
Additional Reads
Optional additional studies from this edition.